Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 8/2013

01-08-2013 | Letter to the Editor

Bevacizumab treatment followed by maintenance in life-threatening POEMS syndrome

Authors: Vittorio Perfetti, Giovanni Palladini, Mara De Amici, Luca Livraghi, Paolo Pedrazzoli, Giampaolo Merlini

Published in: Annals of Hematology | Issue 8/2013

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Dispenzieri A (2012) POEMS syndrome: update on diagnosis, risk-stratification, and management. Am J Hematol 87:804–814PubMedCrossRef
2.
Rosti V, Massa M, Campanelli R, De Amici M, Piccolo G, Perfetti V (2007) Vascular endothelial growth factor promoted endothelial progenitor cell mobilization into the peripheral blood of a patient with POEMS syndrome. Haematologica 92:1291–1292PubMedCrossRef
3.
4.
Dietrich PY, Duchosal MA (2008) Bevacizumab therapy before autologous stem-cell transplantation for POEMS syndrome. Ann Oncol 19:595PubMedCrossRef
5.
Kanai K, Kuwabara S, Misawa S, Hattori T (2007) Failure of treatment with anti-VEGF monoclonal antibody for long-standing POEMS syndrome. Intern Med 46:311–313PubMedCrossRef
6.
Lieu CH, Tran HT, Jiang Z, M. Mao M, Overman MJ, Eng C, Morris J, Ellis LM, Heymach J, Kopetz S (2011). The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. J Clin Oncol 29 (suppl Abstract 3533)
Metadata
Title
Bevacizumab treatment followed by maintenance in life-threatening POEMS syndrome
Authors
Vittorio Perfetti
Giovanni Palladini
Mara De Amici
Luca Livraghi
Paolo Pedrazzoli
Giampaolo Merlini
Publication date
01-08-2013
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 8/2013
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-013-1673-9

Other articles of this Issue 8/2013

Annals of Hematology 8/2013 Go to the issue

Letter to the Editor

Actinomycotic brain abscess as the first clinical manifestation of hereditary hemorrhagic telangiectasia—case report and review of the literature

Original Article

Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia

Review Article

Physical activity, physical fitness and the effect of exercise training interventions in lymphoma patients: a systematic review

Original Article

Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia

Original Article

Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease

Letter to the Editor

Profound thrombocytopenia in patient with ITP treated with chemotherapy for breast cancer and subsequent remission after romiplostim
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits